ArticleSeminars in nephrology2007
Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment.
Article in Seminars in nephrology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 85 citations in OpenAlex.
- Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy.Medical hypotheses · 2013Trial
- Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease.Nutrients · 2022Review
- EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- Growth hormone induces mitotic catastrophe of glomerular podocytes and contributes to proteinuria.Cell death & disease · 2021Article
- The Glomerulus According to the Mesangium.Frontiers in medicine · 2021Review
- Association of Glycated Proteins with Inflammatory Proteins and Periodontal Disease Parameters.Journal of diabetes research · 2020Article
- Role of the 12-lipoxygenase pathway in diabetes pathogenesis and complications.Pharmacology & therapeutics · 2019Review
- Mangosteen peel extract (Iranian journal of basic medical sciences · 2018Article
- Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease.Kidney research and clinical practice · 2018Review
- Preservation of renal function in chronic diabetes by enhancing glomerular glucose metabolism.Journal of molecular medicine (Berlin, Germany) · 2018Review
- FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.Journal of the American Society of Nephrology : JASN · 2018Article
- Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.Kidney international · 2017Article
- PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2017Article
- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.The Journal of biological chemistry · 2017Article
- C-Reactive Protein Promotes Diabetic Kidney Disease in db/db Mice via the CD32b-Smad3-mTOR signaling Pathway.Scientific reports · 2016Article
- G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes.Journal of the American Society of Nephrology : JASN · 2016Article
- Article
- Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases.American journal of physiology. Renal physiology · 2016Review
- MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.Annals of the New York Academy of Sciences · 2015Review
- Diabetic nephropathy--emerging epigenetic mechanisms.Nature reviews. Nephrology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The recognition that the drivers of matrix accumulation is an appropriate therapeutic target for diabetic nephropathy is now accepted by the nephrology and pharmaceutical communities. Interventions focused around transforming growth factor-beta (TGF-beta) likely will be an important area of clinical investigation in the near future. Understanding the various pathways involved in stimulating TGF-beta in the diabetic kidney is of paramount importance in devising strategies to combat the development and progression of diabetic nephropathy. In this review we highlight the major pathways involved in stimulating TGF-beta production by increased glucose levels and discuss the therapeutic implications thereof.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.